Background
==========

The progressive impairment of endothelial function and integrity starts a cascade of events, leading to microcirculation damage, atherosclerosis and common cardiovascular disease (CVD), such as coronary heart disease (CHD), myocardial infarction (MI), heart failure, stroke and peripheral arterial disease (PAD) \[[@B1]\]. Blood-derived endothelial progenitor cells (EPCs) represent the "promoters" of vascular repair providing the rationale for autologous stem cell therapy \[[@B2]\]. The coexistence of multiple classical CVD risk factors negatively influences the number and functional activity of EPCs \[[@B3],[@B4]\]. The number of EPCs has been reported to negatively correlate with hypertension, diabetes mellitus and aging but not smoking \[[@B5]\]. Levels of EPCs are inversely correlated to progression of coronary heart disease \[[@B6]\]. EPCs are currently being tested in different clinical settings including repair of damaged microcirculation, regeneration of ischemic tissues, and bioengineering of vascular grafts (<http://www.clinicaltrials.gov/>).

Clinically, circulating EPCs can be obtained from adult peripheral blood and umbilical cord blood. The number of EPCs in adult blood is known to be significantly lower than in cord blood \[[@B7]\]. EPCs derived from different anatomic locations, just like other somatic stem cells of different sources \[[@B8],[@B9]\], possess unique biological activities: *in vitro* phenotypic studies demonstrated that CB-EPCs have competitive advantage compared with PB-EPCs due to their higher proliferative advantage, as well as better survival rate upon stress-induced apoptosis \[[@B10],[@B11]\]. *In vivo*, tissue-engineered blood vessels generated by peripheral blood- and umbilical cord blood-derived EPCs: blood vessels formed by adult peripheral blood EPCs are unstable and regress within weeks, while umbilical cord blood EPCs form normal-functioning blood vessels that last for more than 4 months \[[@B11],[@B12]\]. Thus, umbilical cord blood EPCs hold great therapeutic potential for cell therapy and vascular engineering.

The above findings suggest that CB-EPCs have enhanced vasculogenic ability compared with adult PB-EPCs. However, the underlying mechanisms are unclear. EPCs from human umbilical cord and adult peripheral blood activate different mechanisms upon high-dose x-ray radiation treatment: CB-EPCs undergo p53 stabilization, Bax-dependent apoptosis and p21-dependent G~1~ and G~2~/M cell cycle checkpoints, while PB-EPCs undergo only radiation-induced senescence \[[@B13]\], indicating unique gene expression patterns in EPCs of different sources. Another level of regulation may lie on microRNAs (miRNAs), which are endogenously expressed small non-coding RNAs of 18-24 nucleotides in length that regulate gene expression on the posttranscriptional level \[[@B14]\]. microRNAs have emerged as master regulators of stem cell lineage differentiation and angiogenesis \[[@B14]\]. microRNAs also play a crucial role in endothelial inflammation, senescence and susceptibility to atherosclerosis: endothelial inflammation is critically regulated by miRNAs such as miR-126 and miR-10a, and endothelial aging is additionally controlled by miR-217 and miR-34a \[[@B15]\]. miR-221 and miR-222, which are encoded from the same miRNA cluster, modulate the angiogenic properties of human umbilical vein endothelial cells (HUVECs) by targeting c-Kit and endothelial nitric oxide synthase (eNOS) \[[@B16]\]. In contrast, miRNA-31 enhances endothelial cell migration and invasion by targeting FAT4, a novel breast cancer tumor suppressor \[[@B17],[@B18]\]. miR-126, -132, -296, -378, and the miR-17 \~ 92 cluster (encoding miR-17, -18a, -19a/b, -20a and miR-92a) also contribute to pathological angiogenesis \[[@B19]-[@B21]\].

In this study we explored protein-coding mRNAs and miRNAs involved in EPC activities. We found that CB-EPCs migrate faster and form tubule structures *in vitro* more efficiently than PB-EPCs do. mRNA and miRNA levels in EPCs of different origins reflect their unique performance.

Methods
=======

Isolation and cultivation of EPCs
---------------------------------

All patients gave informed consent, and the study was approved by the research ethics committee of the Hsinchu Mackay Memorial Hospital, Taiwan (ref number: 11MMHIS040). Protocols of this study were consistent with ethical guidelines provided in the 1975 Helsinki Declaration (<http://www.wma.net/e/policy/b3.htm>). EPC isolation and characterization were done as described previously with minor modifications \[[@B22],[@B23]\]. In brief, blood mononuclear cells (MNCs) isolated by Histopaque-1077 (1.077 g/ml, Sigma, St. Louis, Missouri, USA) density-gradient centrifugation. MNCs (1 × 10^7^) were plated in 2 ml endothelial growth medium-2 (Lonza Ltd., Basel, Switzerland), with supplementation (hydrocortisone, IGF-1, human EGF, human VEGF, human FGF-B, ascorbic acid, GA-1000, heparin and 2% fetal bovine serum) on fibronectin-coated six-well plates at 37 °C in a 5% CO~2~ incubator. After 3 days of culturing, nonadherent cells were removed. Thereafter, the medium were replaced every 2 days, and EPCs colonies emerge 2--4 weeks after the start of MNC culture.

EPC tube formation, transwell cell migration and cell proliferation assays
--------------------------------------------------------------------------

A miR-31 cDNA construct was used in overexpression experiments \[[@B18]\]. Tube formation assay was performed on EPCs to assess their capacity for vasculogenesis, which is believed to be important in new vessel formation. In brief, the *in vitro* tube formation assay was performed by thawing Matrigel at 4 °C overnight, and then placed it in a 96-well plate at 37 °C for 1 h to allow the matrix solution to solidify. EPCs were harvested with trypsin/EDTA, and 1 × 10^4^ EPCs were placed on Matrigel with EGM-2 medium or serum-free DMEM and incubated at 37 °C for 6 h. Tubule formation was inspected under an inverted light microscope (100x). Four representative fields were taken. For 3D angiogenesis assay, collagen type I acidic solution were mixed with 1/2 volume of basic conditioned medium with 0.2 ug/ml SDF-1α (R&D system, Minneapolis, MN USA) and solidify 30 minutes in 96-well plate at 37 °C in a 5% CO~2~ incubator. 10^5^ cells per well were seeded and assayed.

Cell migration ability was evaluated using Costar Transwell® Polycarbonate Permeable Supports (Corning, NY, USA) as previously described \[[@B18]\]. The degree of cell proliferation was examined by the MTT assay system (Invitrogen, USA) according to the manufacturer's instructions.

mRNA microarray and bioinformatics analysis
-------------------------------------------

Total RNA sample preparation, cRNA probe preparation, array hybridization and data analysis were done as described previously \[[@B24]\]. Affymetrix^TM^ HG-U133 Plus 2.0 whole genome chips were used. RMA log expression units were calculated from Affymetrix GeneChip array data using the 'affy' package of the Bioconductor (<http://www.bioconductor.org>) suite of software for the R statistical programming language (<http://www.r-project.org>). The default RMA settings were used to background correct, normalize and summarize all expression values. Significant differences between the sample groups was identified using the 'limma' (Linear Models for Microarray Analysis) package of the Bioconductor suite, and an empirical Bayesian moderated t-statistic hypothesis test between the two specified phenotypic groups was performed \[[@B25]\]. To control for multiple testing errors, we then applied a false discovery rate algorithm to these *p* values in order to calculate a set of *q* values, thresholds of the expected proportion of false positives, or false rejections of the null hypothesis \[[@B26]\]. Heat maps were created by the dChip software (<http://www.dchip.org/>). Array data are deposited in the Gene Expression Omnibus (GEO) database with an accession number of GSE39763. Part of the PB EPC array data were from a public GEO dataset GSE23203 (GSM663476-81) and 1 CB-EPC data from GSE12891 (GSM323169).

Gene annotation was performed by our ArrayFusion web tool (<http://microarray.ym.edu.tw/tools/arrayfusion/>) \[[@B27]\]. Gene Ontology database search were performed by the DAVID 6.7 Bioinformatics Resources (<http://david.abcc.ncifcrf.gov/>). The Ingenuity Pathway Analysis (IPA) web tool developed by Ingenuity Co. (<http://www.ingenuity.com>) was used to construct functional regulatory networks of gene profiles. IPA uses the Ingenuity Pathways Knowledge Base to identify known interactions between focus genes and other genes that are not in the gene list. IPA then determines a statistical score for each network according to the fit of the network to the set of focus genes. The score is the negative log of p and denotes the likelihood of the focus genes in the network being found together by chance.

Small RNA sequencing (smRNA-Seq) and data analysis
--------------------------------------------------

Total RNA was collected and small RNA fractions were sequenced by Illumina Solexa Genome Analyzer IIx (GAIIx; Illumina, San Diego, CA USA) according to manufacturer's instruction. For data analysis, quality Fastq sequences, which were without poly-A, ambiguous nucleotides or a 5' adapter, yet flanking 6-18 nt of 3' adapter sequence, had the adapter sequences trimmed and the identical sequences were then collapse to unique sequences. The resulting unique sequences that did not align to mRNA database (UCSC genome browsers) but were aligned to known microRNA sequences (miRBase R18; <http://www.mirbase.org/>) were subjected into further quantification analysis. Sequencing reads were calculated to obtain a RPKM (reads per kilobase of exon model per million mapped reads) \[[@B28]\] value as C/LMN x 10^9^, where C = read numbers aligned to given miRNA chromosomal region, L = length of miRNA, M = multiple mapping numbers across all miRNA regions and N = total read numbers that map to human genome sequence. microRNA target prediction was done by the miRTar webtool (<http://mirtar.mbc.nctu.edu.tw/human/>) \[[@B29]\].

RNA extraction and real-time quantitative polymerase chain reaction (qPCR)
--------------------------------------------------------------------------

RNA extraction and reverse transcription were performed as previously described \[[@B18]\]. The expression of mature human miRNAs was determined by a stem-loop real-time PCR system using the appropriate primer pairs. The universal PCR reverse primer for the miRNAs was 5'-GTGCAGGGTCCGAGGT-3'. miR-31-specific primers were used \[[@B18]\] and the primer sequences are in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1. Primer sequences of all other genes and miRNAs are also in Additional file [1](#S1){ref-type="supplementary-material"}*:* Figure S1. The miRNA expression data were normalized against the average values of U6 snRNA, U48 snRNA and 5S rRNA, while the miRNA expression data were normalized against the average values of GAPDH and beta-actin.

Results
=======

Isolation and characterization of human EPCs from cord blood and adult peripheral blood
---------------------------------------------------------------------------------------

EPCs were obtained from cord blood or peripheral blood of healthy subjects as described \[[@B23]\]. Blood MNCs that were initially seeded on fibronectin-coated wells were round, and outgrowth EPCs with a cobblestone-like morphology similar to mature endothelial cells grew to confluence at days 14-21 (not shown). Cultured EPCs were subjected into Traswell cell migration assays (Figure [1](#F1){ref-type="fig"}A), tube formation assays (Figure [1](#F1){ref-type="fig"}B), or MTT assays (Figure [1](#F1){ref-type="fig"}C). Clearly EPCs from CB migrated faster, proliferated faster and formed microvasculature structure more efficient *in vitro* (Figure [1](#F1){ref-type="fig"}A-C).

![**Different angiogenic abilities between EPCs isolated from different anatomic locations.** ( **A**) EPCs from cord blood (CB-EPCs) migrate faster than those from adult peripheral blood (PB-EPCs). EPCs from different sources were subjected to Transwell cell migration assays, and migrated cells were stained (representative pictures are shown) and counted (left panel, n = 3). \*:P \< 0.05 ( **B**) CB-EPCs form better microvasculature structures *in vitro*. EPCs were subjected onto MatriGel for tube formation assays (representative pictures are shown). Tube lengths of formed microvascular structure were counted (left panel, n = 3). \*:P \< 0.05 ( **C**) Cell proliferation assays show CB-EPCs grow faster *in vitro*. Cultured EPCs were subjected into MTT assays for monitoring cell proliferation rate.](1471-2164-13-447-1){#F1}

Gene expression signatures and functional modules of different EPCs
-------------------------------------------------------------------

To provide the underlying mechanisms for observed phenotypes, we explored the transcriptome patterns of different EPCs. Protein-coding mRNAs were deciphered first by Affymetrix whole-genome microarrays. A total of 753 probe sets (positive false discovery rate (pFDR) q \< 0.005) were found unique to CB-EPC, while another 431 to PB-EPC (Figure [2](#F2){ref-type="fig"}A & Additional file [2](#S2){ref-type="supplementary-material"}*:* Figure S2 online). A PCA plot using these 1184 probe represents their differentiating power (Figure [2](#F2){ref-type="fig"}B).

![**Distinct gene expression patterns of different EPCs.** ( **A**) A heat map showing genes more abundant in CB-EPCs. Columns represent EPC samples from different donors, while rows represent probe sets. Genes in red: increased expression; in blue: decreased. ( **B**) A principle component analysis (PCA) plot using genes differentially expressed between different EPCs. Each spot represents a single array sample. ( **C**) The unique biological functions of CB-EPCs. CB-EPC-enriched genes were subjected to a Gene Ontology (GO) database search. These categories were selected from the "Biological Process" organizing principle in the GO database (<http://www.geneontology.org/>). The number of genes, gene symbols, and p values for each category that are significantly enriched are listed (p \< 0.05). (**D**) Validation of mRNA array data by qPCR. Mean gene expression levels of EPC genes were compared to the average CT values of GAPDH and beta-actin controls. Results are expressed as mean ± standard deviation. \*:P \< 0.05 ( **E**) Canonical pathways enriched in CB-EPCs according to the analysis of the Ingenuity Pathway Analysis (IPA) web tool. ( **F**) Schematic representation of the "FLT3 Signaling in Hematopoietic Progenitor Cells" pathway. CB-EPC genes assigned to this pathway are indicated and in red.](1471-2164-13-447-2){#F2}

The above gene list gave us a primary insight into the unique composition of differential EPCs but reflected little on EPC functions. To understand more how gene expression profiles might correlate with EPC biology and to provide quantitative evidence, signature probe sets were subjected to Gene Ontology (GO) database search for finding statistically over-represented functional groups within these genes. Given that the whole human transcriptome was represented by the microarray analysis, this analysis was not biased toward the coverage of the microarray. The GO categories of the biological processes being statistically overrepresented (*p* \< 0.05) among CB-EPC genes are presented in Figure [2](#F2){ref-type="fig"}C. The most significant biological process for CB-EPCs is cell cycle (349 genes, *p* = 1.14 × 10^-3^), especially the mitotic cell cycle (19 genes, *p* = 1.41 × 10^-4^; Figure [2](#F2){ref-type="fig"}C). Vasculature development genes (16 genes, *p* = 1.01 × 10^-2^), especially those involved in angiogenesis (10 genes, *p* = 3.73 × 10^-2^), are also significantly higher in CB-EPCs (Figure [2](#F2){ref-type="fig"}C). The abundant expression of CB-EPC or PB-EPC genes were verified by RT-qPCR (Figure [2](#F2){ref-type="fig"}D). A famous tumor suppressor TP53 was more abundant in PB-EPC, while angiogenic genes ANGPTL4 and CDK1 in CB-EPCs (Figure [2](#F2){ref-type="fig"}D). Other related predominant processes include those pertaining to DNA damage checkpoint (8 genes, *p* = 5380 × 10^-4^, not shown), protein transport (38 genes, *p* = 0.0034), and post-translational protein modification (53 genes, *p* = 0.0045, especially those involve in phosphorylation (37 genes, *p* = 0.0124)).

We also subjected CB-EPC genes into KEGG and Ingenuity Pathway Analysis (IPA) database search for disclosing enriched pathways and functional modules. More information was revealed from Ingenuity database search. The "G2/M DNA damage checkpoint regulation" canonical pathway ranks the No. 1 most significant pathway found among CB-EPC genes (Figure [2](#F2){ref-type="fig"}E). Genes involved in the "FLT3 signaling in hematopoietic progenitor cells" pathway is also overexpresssed in CB-EPCs (Figures [2](#F2){ref-type="fig"}E-F). Also enriched in CB-EPCs are HIF1α (hypoxia-inducible transcription factor 1 alpha) signaling, cardiac hypertrophy signaling, renin-angiotensin signaling and NFAT in cardiac hypertrophy pathways (Figure [2](#F2){ref-type="fig"}E), reflecting the pro-angiogenic nature of CB-EPCs. By KEGG definition, genes involved in cell cycle are again found significant (Additional file [3](#S3){ref-type="supplementary-material"}*:* Figure S3). Database search and functional module assays explain in part why CB-EPCs amplification quicker (Figure [1](#F1){ref-type="fig"}C).

Unique miRNA expression profiles of different EPCs revealed by small RNA sequencing (smRNA-Seq)
-----------------------------------------------------------------------------------------------

Another level of gene expression regulation is through microRNAs. To provide a more comprehensive view of transcriptome profiles of EPCs from different sources, we determined miRNA profiles of different EPCs by sequencing the small RNA fractions of both EPCs. Illumina Solexa platform generated 9.7 million high-quality sequence reads for PB-EPCs, and another 11 million reads for CB-EPCs (Figure [3](#F3){ref-type="fig"}A, *upper*). We constructed an in-house pipeline (illustrated in Figure [3](#F3){ref-type="fig"}A) for analyzing sequencing data. The initial operations included identifying sequence matches to the mRNA database in order to eliminate degraded mRNA exon reads. Then non-exonic reads that match previously annotated miRNAs deposited in the miRBase database (release 18) were subjected to normalization and quantitative profiling. The expression of known miRNAs were converted into RPKM, and then filtered using a threshold RPKM \> 100. A total of 104 miRNAs were differentially expressed between 2 EPCs, with 54 being more abundant in CB-EPCs while another 50 in PB-EPCs (≥1.5 folds; Figure [3](#F3){ref-type="fig"}B & Tables [1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}). The differential expression of miR-31, miR-18a, miR-10a and miR-26a were verified by RT-qPCR (Figures [3](#F3){ref-type="fig"}C-D).

![**Differentially expressed miRNAs between CB- and PB-EPCs discovered by smRNA-Seq.** ( **A**) A table summarizes reads number ( *upper*) and a flowchart describes the data analysis pipeline for quantification of known miRNAs from smRNA-Seq data ( *lower*). ( **B**) Differential expressed miRNAs between cord blood EPCs and adult peripheral blood EPCs. ( **C-D**) qPCR validation of smRNA-Seq data. Mean miRNA expression levels were compared to the average CT values of U6 snRNA + U48 snRNA + 5S rRNA controls. miRNAs more abundant in CB-EPC ( **C**) or PB-EPC ( **D**) were verified. \*:P \< 0.05 ( **E**) A major functional genetic network composed of multiple PB-EPC microRNAs (in green) and CB-EPC genes (in red). This network is displayed graphically as nodes (gene products) and edges (biological relationships between nodes) mapped by the Ingenuity Pathway Analysis (IPA) tool. The intensity of the node color indicates the degree of differential expression. Hub miRNAs in this genetic network are shown.](1471-2164-13-447-3){#F3}

###### 

54 miRNAs over-expressed in CB-EPC

      **Name**       **chromosome location**    **PB RPKM**   **CB RPKM**   **Fold (CB/PB)**   **PB rank**   **CB rank**
  ---------------- --------------------------- ------------- ------------- ------------------ ------------- -------------
    hsa-mir-136     chr14:101351053-101351075        0         495.64316       9.90E+307           770           95
    hsa-mir-376c    chr14:101506069-101506089    1.2448007     1174.4226      943.4623551          483           68
    hsa-mir-494     chr14:101496018-101496039    3.3418648     3083.2217      922.6051575          382           33
   hsa-mir-376a\*   chr14:101507125-101507146    3.1190746     2104.9521      674.8643011          389           47
    hsa-mir-376a    chr14:101506455-101506475    0.7002004     359.68243      513.6849822          542           106
                    chr14:101507162-101507182                                                                      
    hsa-mir-377     chr14:101528431-101528452   0.89116406     305.87003      343.2252755          514           116
    hsa-mir-410     chr14:101532298-101532318    1.4004008     399.5301       285.2969664          468           101
    hsa-mir-381     chr14:101512305-101512326    6.6837296     1888.779       282.5935687          316           54
    hsa-mir-411     chr14:101489677-101489697    5.134803      1427.5367      278.0119705          341           63
    hsa-mir-889     chr14:101514286-101514306    1.4004008     309.84427      221.2539939          468           113
    hsa-mir-379     chr14:101488408-101488428    27.541208     4422.998       160.5956427          221           27
   hsa-mir-369-3p   chr14:101531978-101531998    5.6016035     868.6908       155.0789519          334           81
    hsa-mir-134     chr14:101521031-101521052   10.9167595     910.0818       83.36556283          281           77
    hsa-mir-29b     chr7:130562226-130562248     84.74453      6061.3887      71.52542707          162           20
                    chr1:207975795-207975817                                                                       
   hsa-mir-222\*     chrX:45606479-45606500      25.843756     1562.2592      60.45016057          223           61
     hsa-mir-31      chr9:21512157-21512177      347.53278     15717.314      45.22541442          93             7
   hsa-mir-127-3p   chr14:101349372-101349393    64.60941      2614.9524      40.47324376          174           39
   hsa-mir-654-3p   chr14:101506606-101506627    16.932117      517.527        30.5648136          255           91
    hsa-mir-146a    chr5:159912379-159912400     1061.7109     7229.664       6.809446903          65            15
    hsa-mir-216a     chr2:56216155-56216176      462.73697     3054.6147      6.601190089          84            34
    hsa-mir-18b     chrX:133304114-133304136     95.57735      621.04553      6.497831652          152           90
   hsa-mir-24-2\*    chr19:13947140-13947161     126.99086     810.7064       6.383974406          144           84
    hsa-mir-503     chrX:133680401-133680423     83.323845     498.72934      5.985433581          163           94
    hsa-mir-18a      chr13:92003010-92003032     116.24848     684.41486      5.887516637          147           87
    hsa-mir-4792     chr3:24562903-24562920      56.91072      308.37952      5.418654341          181           114
    hsa-mir-19a      chr13:92003193-92003215     168.31697     886.21814      5.265174034          130           80
    hsa-mir-19b     chrX:133303713-133303735,    351.0184      1759.4749       5.01248624          92            58
                     chr13:92003499-92003521                                                                       
    hsa-mir-185      chr22:20020676-20020697     130.77832     639.70306      4.891506941          142           89
    hsa-mir-424     chrX:133680710-133680731     326.61172     1557.3126      4.768085481          97            62
     hsa-mir-24      chr9:97848346-97848367      39987.26      172634.36      4.317234039           5             2
                     chr19:13947103-13947124                                                                       
    hsa-mir-196a     chr17:46709894-46709915     93.497955     398.9361       4.266789578          156           102
                     chr12:54385546-54385567                                                                       
    hsa-mir-130a     chr11:57408725-57408746     319.70517     1143.3563      3.576283424          98            70
    hsa-mir-345     chr14:100774213-100774234    137.23924     455.79385      3.321162737          138           98
     hsa-mir-32     chr9:111808552-111808573     94.68617      312.1079       3.296235343          153           112
   hsa-mir-339-3p     chr7:1062591-1062613       116.35501     376.72174      3.237692472          146           105
    hsa-mir-186      chr1:71533364-71533385      1265.8989     3930.9248      3.105243871          57            30
    hsa-mir-20b     chrX:133303880-133303902     393.07117     1119.9288      2.849175634          90            72
   hsa-mir-542-3p   chrX:133675394-133675415     302.77307     758.6524       2.505679914          100           85
    hsa-mir-877      chr6:30552109-30552128      134.05331     333.61777      2.488694759          140           110
    hsa-mir-106b     chr7:99691666-99691686      1116.7422     2731.2852      2.445761609          62            36
    hsa-mir-452     chrX:151128150-151128171     466.9701      1105.1763      2.366696069          82            73
     hsa-mir-22       chr17:1617208-1617229      1037.9835     2326.5046       2.24136954          66            42
   hsa-mir-374a\*    chrX:73507130-73507151      1247.1844     2619.4692      2.100306258          60            38
    hsa-mir-29c     chr1:207975210-207975231     1326.5715     2675.448        2.01681402          53            37
    hsa-mir-29a     chr7:130561507-130561528     1443.6847     2802.1428      1.940965919          50            35
    hsa-mir-30e      chr1:41220043-41220064      5007.227      9227.503       1.842836963          26            10
    hsa-mir-99a      chr21:17911421-17911442     2773.0786     5025.056       1.812085673          41            24
    hsa-mir-20a      chr13:92003326-92003348     1287.8253     2302.079       1.787570876          54            43
    hsa-mir-15a      chr13:50623303-50623324     483.79068     822.4292       1.699969086          81            83
    hsa-mir-100     chr11:122022983-122023004    4361.801      7380.455       1.692065961          28            14
    hsa-mir-106a    chrX:133304274-133304296     1250.3193     2036.8033      1.629026521          59            50
     hsa-mir-17      chr13:92002872-92002894     1266.1599     2058.4065      1.625708175          56            48
    hsa-mir-27a      chr19:13947261-13947281     5321.171      8077.8022       1.51804973          25            12
   hsa-mir-140-5p    chr16:69967006-69967027     334.1866      501.82477      1.501630436          96            93

###### 

50 miRNAs over-expressed in PB-EPC

      **Name**        **chromosome location**    **PB RPKM**   **CB RPKM**   **Fold (CB/PB)**   **PB rank**   **CB rank**
  ----------------- --------------------------- ------------- ------------- ------------------ ------------- -------------
    hsa-let-7b\*      chr22:46509625-46509646     358.35938     26.206163      -13.67462226         91            280
    hsa-mir-15b\*    chr3:160122433-160122454     695.9995       72.2731       -9.630132096         73            215
    hsa-mir-1290      chr1:19223572-19223590      337.0359      35.74031       -9.43013365          95            258
     hsa-mir-15b     chr3:160122395-160122416     2379.7402     379.11118      -6.27715648          42            104
   hsa-mir-574-3p     chr4:38869713-38869734      435.55652     86.03938       -5.062292639         85            201
     hsa-mir-25       chr7:99691194-99691215      1534.8059     319.06284      -4.810356167         49            111
    hsa-mir-148a      chr7:25989542-25989563      1073.8528     231.33844      -4.641912516         63            134
    hsa-mir-30e\*     chr1:41220085-41220106      3634.1675     920.4779       -3.948131183         34            76
    hsa-mir-30a\*     chr6:72113257-72113278      4051.6772     1061.4753      -3.817024475         29            74
     hsa-mir-365     chr16:14403197-14403218,     653.44617     171.86374      -3.802117713         75            149
                      chr17:29902497-29902518                                                                       
    hsa-mir-28-3p    chr3:188406622-188406643     1804.1597     485.26227      -3.717906401         44            96
     hsa-mir-23b      chr9:97847547-97847567      8076.4937     2225.3198      -3.629363159         22            45
   hsa-mir-146b-5p   chr10:104196277-104196298    1253.9794     349.96533      -3.583153223         58            108
     hsa-mir-92b     chr1:155165028-155165049     318.21985     90.19796       -3.528016044         99            195
     hsa-mir-197     chr1:110141562-110141583     528.68317     149.92363      -3.526349849         79            156
   hsa-mir-140-3p     chr16:69967045-69967065     12527.033     3577.7405      -3.501381109         12            32
     hsa-mir-598      chr8:10892731-10892752      489.91757     143.68575      -3.40964619          80            161
     hsa-let-7b       chr22:46509571-46509592     8703.284      2554.5288      -3.407001714         20            40
     hsa-mir-378     chr5:149112430-149112450     32406.646     10804.972      -2.999234612          7             9
   hsa-mir-455-3p    chr9:116971767-116971787     548.25714     187.93459      -2.917276378         78            142
    hsa-mir-193b      chr16:14397874-14397895     415.28253     143.25558      -2.898892525         87            162
     hsa-mir-92a     chrX:133303574-133303595     3847.525      1331.7456      -2.889084071         33            64
                      chr13:92003615-92003636                                                                       
     hsa-mir-93       chr7:99691438-99691460      3588.8904      1322.95       -2.712793681         35            65
     hsa-let-7c       chr21:17912158-17912179     15608.78      5758.0083      -2.710794981         11            22
     hsa-mir-30b     chr8:135812813-135812834     1066.1298     400.58517      -2.661431026         64            100
     hsa-mir-10a      chr17:46657266-46657288     17177.37      6494.583       -2.644876507          8            17
     hsa-mir-10b     chr2:177015057-177015079     16707.91      6317.509       -2.644699042         10            19
     hsa-let-7d       chr9:96941123-96941144      9057.177      3642.2817      -2.48667669          16            31
   hsa-mir-151-3p    chr8:141742686-141742706     17066.672     7218.801        -2.3641976           9            16
     hsa-mir-30c      chr1:41222972-41222994      4914.325      2188.866       -2.245146574         27            46
                      chr6:72086706-72086728                                                                        
     hsa-let-7e       chr19:52196046-52196067     8924.559      3985.3586      -2.239336505         17            29
    hsa-mir-320a      chr8:22102488-22102509      757.8811      340.61673      -2.225026058         70            109
     hsa-let-7a      chr11:122017276-122017297    65673.34      30296.24       -2.16770596           3             5
                      chr9:96938244-96938265                                                                        
                      chr22:46508632-46508653                                                                       
     hsa-mir-99b      chr19:52195871-52195892      8875.32      4099.9907      -2.164717105         19            28
     hsa-let-7f       chr9:96938635-96938656      37668.82      17587.143      -2.141838501          6             6
                      chrX:53584207-53584228                                                                        
     hsa-mir-23a      chr19:13947409-13947429     10271.966     4879.2725      -2.105224908         14            26
    hsa-mir-125b      chr21:17962573-17962594     3983.9465     1976.1088      -2.016056252         30            51
                     chr11:121970517-121970538                                                                      
   hsa-mir-125a-5p    chr19:52196521-52196544     1764.7084      897.535       -1.966172238         46            79
   hsa-mir-361-5p     chrX:85158686-85158707      399.24158     205.20401      -1.945583714         89            138
     hsa-mir-16      chr3:160122542-160122563     3338.2983     1761.0107      -1.895671787         38            57
                      chr13:50623163-50623184                                                                       
    hsa-mir-1307     chr10:105154058-105154079    553.6359      294.46994      -1.880110072         77            118
    hsa-mir-320b     chr1:224444751-224444772     661.5061      356.97238      -1.853101632         74            107
                     chr1:117214409-117214430                                                                       
     hsa-mir-217      chr2:56210155-56210177      10865.332     5983.509       -1.815879612         13            21
   hsa-mir-769-5p     chr19:46522219-46522240     421.96628     236.17818      -1.786643796         86            133
     hsa-mir-191      chr3:49058105-49058127      3378.5552     1927.2273      -1.753065246         36            52
   hsa-mir-139-5p     chr11:72326147-72326168     301.21347     178.96194      -1.683114689         101           145
     hsa-mir-26a      chr12:58218441-58218462     3344.9814     2055.193       -1.627575318         37            49
                      chr3:38010904-38010925                                                                        
    hsa-mir-103a     chr5:167987909-167987931     8117.7095     5296.3853      -1.532688624         21            23
                       chr20:3898188-3898210                                                                        
     hsa-mir-107      chr10:91352513-91352535     3862.0547     2533.423       -1.524441319         31            41
    hsa-mir-151b     chr14:100575775-100575792    610.3607       405.608       -1.504804392         76            99

Applying the genetic network analysis function in the IPA web tool, we searched for miRNA-mRNA pairs and networks in CB-EPCs. PB-EPC miRNAs, such as miR-10a/b, miR-26a, miR-103a, miR-107, miR-139-5p, miR-151b, miR-361-5p, miR-365 and miR-1290, were found to be master regulators of a subset of CB-EPC protein-coding mRNAs (Figure [3](#F3){ref-type="fig"}E). The collective reduction of these miRNAs in CB-EPCs may explain in part why genes, such as ETV1 (Figure [3](#F3){ref-type="fig"}E), in this genetic network are more abundant in CB-EPCs.

Most of the differentially expressed miRNAs have not been linked to angiogenesis. MiR-410 is involved in regulating secretion \[[@B30]\]. MiR-15a, -20b and -24 are reduced in the plasma of type 2 diabetes patients, which intend to have poor angiogenesis \[[@B31]\]. *In vitro*, miR-503 expression in ECs is upregulated in culture conditions mimicking diabetes mellitus (high D-glucose) and ischemia-associated starvation (low growth factors). Forced miR-503 expression inhibits EC proliferation, migration, and network formation on Matrigel \[[@B32]\]. MiR-24 is considerably upregulated after cardiac ischemia and is enriched in cardiac endothelial cells. MiR-24 induces endothelial cell apoptosis, abolishes endothelial capillary network formation on Matrigel, and inhibits cell sprouting from endothelial spheroids by targeting of the stemness transcription factor GATA2 and the p21-activated kinase PAK4 \[[@B33],[@B34]\]. MiR-100 has an antiangiogenic function by modulating proliferation, tube formation, and sprouting activity of endothelial cells and migration of vascular smooth muscle cells and functions as an endogenous repressor of the serine/threonine protein kinase mammalian target of rapamycin (mTOR) \[[@B35]\]. MiR-29b can suppress tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression in hepatocellular carcinoma (HCC) \[[@B36]\]. MicroRNAs from the miR-17 \~ 92 cluster are known to contribute in pathological angiogenesis \[[@B19]-[@B21]\], and 5 out of 6 members (including miR-17, -18a, -19a/b and -20a) were overexpressed in CB-EPCs (Table [1](#T1){ref-type="table"}).

miR-31 as a novel EPC angiogenic miRNA
--------------------------------------

To identify more pro-angiogenic miRNAs involved in EPC activity, we examined which miRNA(s) may contribute in EPC angiogenesis. MiR-31 is a known pro-angiogenic and pro-lymphangiogenic miRNA which induce motility in both matured blood vessel and lymphatic endothelial cells \[[@B18],[@B37]\]. Knocking down endogenous miR-31 levels reduced tube formation and cellular migration abilities in CB-EPCs (Figures [4](#F4){ref-type="fig"}A-C), suggesting a pro-angiogenic role of miR-31 in both progenitor and mature type endothelial lineage cells. On the other hand, overexpressing miR-31 in PB-EPCs helped to recapitulate some of the functions of CB-EPCs (Figure [4](#F4){ref-type="fig"}D). Over-expressing miR-31 in PB-EPC or knocking down endogenous CB-EPC miR-31 level did not affect cell proliferation rate at a significant level in the first 24 hours of transfection (Additional file [4](#S4){ref-type="supplementary-material"}*:* Figure S4). The tube formation and cell migration effects we observed should due to mainly the pro-angiogenic activity of miR-31.

![**miR-31 is involved in EPC activities.** ( **A-C**) Knocking down endogenous miR-31 in CB-EPCs. Anti-miR-31 antagomiR or the siGFP control (Ctrl) was introduced into CB-EPCs by electroporation, and 2 days later EPCs were subjected to tube formation ( *A*) and Transwell cell migration assays ( *B*). Cellular miR-31 levels were detected by RT-qPCR ( *C*, left panel; n = 3), and migration assay and tube formation assay results were also quantified ( *C*, middle and right panels; n = 3, using cells from 3 batches of donors). ( **D**) Overexpressing miR-31 in PB-EPCs stimulates EPC angiogenic abilities. Cellular miR-31 levels were detected by RT-qPCR (left panel; n = 3). Cellular migration assays and tube formation assays were done, and results were quantified (middle and right panels; n = 3, using cells from 3 batches of donors).](1471-2164-13-447-4){#F4}

Discussion
==========

Endothelial cells from the internal barrier of the vasculature, and play fundamental roles in vascular development and disease. The regulation of angiogenesis depends not only on the number of circulating EPC but also on their functions \[[@B38]\]. Aberrant EPC activity and the resulting abnormal angiogenesis cause a variety of diseases, such as ischemia, cancer and metastasis. On the other hand, these cells are also potential cell source for cellular therapies aiming to enhance the neovascularization of tissue engineered constructs or ischemic tissues \[[@B39]\]. Atherosclerotic heart disease remains one of the major causes of morbidity and mortality worldwide. Currently, vascular revascularization techniques, including balloon angioplasty and stenting, have been well developed. However, post-angioplasty restenosis substantially limit long-term benefits of heart revascularization procedures. Therapeutic progenitor cell transplantation bear potential for organ vascularization regeneration in various pathological states \[[@B40]\]. The application of EPC in stenting technology during vascular revascularization is the Genous EPC stent (OrbusNeich, Wanchai, Hong Kong), which is a stainless-steel stent coated with immobilized human anti-CD34 monoclonal antibodies that allow the stent surface to \"capture\" EPCs in the blood to accelerate endothelialization of the stent strut. In recent clinical trial, it shows promise result in reducing the risk of stent thrombosis by facilitating rapid endothelialization on stent strut \[[@B41]\].

An increasing number of studies shows that miRNAs, or angiomiRs, play a crucial role in regulating various aspects of cancer biology, including angiogenesis. Manipulating miRNAs in the settings of pathological vascularization therefore represents a new therapeutic approach \[[@B14]\]. On the other hand, there are still challenges to harnessing EPCs for cell therapy. One of these is their rarity (0.01-0.02 per 10^6^ mononuclear cells), which makes EPC isolation challenging. *In vitro* cultivation and amplification of EPCs is therefore required before these cells may be appropriately investigated for use in clinical therapies. However, it is crucial to maintain EPC activity during such *in vitro* manipulation. Understanding the basic EPC biology will help to develop new biomarkers for monitoring EPC activities. In this report, we identified EPCs, especially those from cord blood, exploit several cellular genetic groups and miRNA pathways to regulate their angiogenesis activities. Transcriptome information will eventually help to develop new clinical applications as mentioned above.

When PB-EPC genes were subjected into GO database search, we found these genes are enriched in both Wnt receptor signaling (8 genes including CREBBP, DVL3, NFAT5, PPARD, RAC1, TBL1X, TCF7L2, TP53; p= 0.019) and positive regulation of I-kappaB kinase/NF-kappaB cascade (6 genes including LITAF, MAP3K3, MAP3K7IP2, MUL1, TRIM13, PSMB7; p = 0.048). Genes involved in the induction of apoptosis are also more abundant in PB-EPCs (15 genes, p = 0.006). KEGG and IPA database search also revealed that genes involved in both Wnt signaling (p = 0.020) and MAPK (13 genes, including ACVR1B, ARRB1, DDIT3, DUSP3, DUSP16, ELK4, GADD45B, MAP3K3, MAP3K7IP1, MAP3K7IP2, MAPKAPK2, RAC1 and TP53; p = 012) pathways are more abundant in PB-EPCs (Additional file [5](#S5){ref-type="supplementary-material"}*:* Figure S5, Additional file [6](#S6){ref-type="supplementary-material"}*:* Table S1). IPA analysis also revealed the Wnt/β-catenin signaling pathway may be more active in PB-EPCs (Additional file [7](#S7){ref-type="supplementary-material"}*:* Table S2). The Wnt signaling system regulates vascular patterning in the developing embryo \[[@B42]\]. It has recently been documented that Wnt1 is a proangiogenic molecule of human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner \[[@B43]\]. Our work further supports a crucial role of Wnt pathway in adult EPCs, and Wnt proteins may be therapeutically deployed to increase blood flow and angiogenesis in adult ischemic tissues.

In this study we applied RNA sequencing (RNA-seq) technology, instead of microRNA chips, for deciphering EPC miRNomes. This is due to the fact that microarray application in miRNome research has several limitations, including hybridization and cross-hybridization artifacts, dye-based detection issues and design constraints that preclude or seriously limit the detection of newly discovered miRNAs or previously unmapped, novel miRNAs \[[@B44]\]. These issues have made it difficult for standard array designs to provide full sequence comprehensiveness (coverage of all possible genes, including "unknown" ones, in large genomes) or transcriptome comprehensiveness (reliable detection of all RNAs of all prevalence classes, including the least abundant ones that are physiologically relevant). Studies using this method have already altered our view of the extent and complexity of eukaryotic transcriptomes \[[@B44]\]. RNA-seq has also delivered a sharp rise in the rate of novel microRNA discovery in the current miRBase R18 release (2011 Nov; <http://microrna.sanger.ac.uk/sequences/>), which is the primary online repository for all microRNA sequences and annotation.

One of the CB-EPC-dominant microRNAs is miR-31, a pro-angiogenic miRNA that enhances endothelial cell migration \[[@B18],[@B37]\]. MiR-31 has recently been documented as a signature BEC miRNA that negatively regulates lymphatic endothelial cell identity and lymphatic vascular development by targeting Prox1, a transcription factor that functions as a master regulator of lymphatic lineage-specific differentiation \[[@B45]\]. In the present study, we further showed that miR-31 is a dominant miRNA in CB-EPCs, and its overexpression is crucial for EPCs to possess superior angiogenic ability (Figure [4](#F4){ref-type="fig"}). Unmasking the roles of small RNA-mediated gene regulation in EPC activity will be crucial and will provide new insights into regenerative and reparative medicine. We envision that our report will serve as a resource for future miRNA studies that aim to improve understanding of the various regulatory ultimately modulating EPC and EC activities.

For miRNAs more abundant in PB-EPCs, miR-217 modulates endothelial cell senescence via silent information regulator 1 (sirT1) \[[@B46]\]. The levels of miR-330 and let-7e are higher in the myocardial microvascular endothelial cells (MMVEC) in type 2 diabetic Goto-Kakizaki (GK) rats, which have impaired angiogenesis \[[@B47]\]. MiR-93, member of the miR-106b ∼ 25 cluster (a paralog of the miR-17 ∼ 92 cluster), in tumor cells possesses oncogenic and angiogenic activities \[[@B48]\]. Both microRNA-125a-5p and miR-125b are overexpressed in PB-EPCs (Table [2](#T2){ref-type="table"}), and their role in inhibiting endothelin-1 expression in vascular endothelial cells has been reported \[[@B49]\]. miR-10a regulates a proinflammatory phenotype in athero-susceptible endothelium *in vivo*\[[@B50]\]. The collective effects of these miRNAs in EPC biology are still awaited to be elucidated.

Conclusions
===========

In summary, our results reveal a series of differentially expressed miRNAs and protein-coding genes that have not previously been associated with EPC biology. This study therefore provides a road map for future mechanistic studies of EPC migration and microvasculature formation, which should eventually help to improve our understanding of angiogenesis, and will also benefit the development of new therapeutic approaches that target the inhibition of pathogenic angiogenesis in tumors, the stimulation of angiogenesis in patients with cardiovascular diseases, stroke or diabetes.
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Distribution of CB-EPC cell cycle genes according to the KEGG database. CB-EPC genes are labeled with red stars. The P value is also shown.

###### 

Click here for file

###### Additional file 4 Figure S4

Over-expressing miR-31 in PB-EPC (A) or knocking down endogenous miR-31 in CB-EPC (B) did not affect cell proliferation rate at a significant level in the first 24 hours of transfection.
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Distribution of PB-EPC genes in the Wnt signaling pathway according to the KEGG database. PB-EPC genes are labeled with red stars.
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Distribution of PB-EPC genes in the MAPK signaling pathway according to the KEGG database. PB-EPC genes are labeled with red stars.
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Distribution of PB-EPC genes in the Wnt signaling pathway according to the IPA web tool. Involved PB-EPC genes are in green and indicated.
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